Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2019
HTA in the European Union: osteoporosis screening without proof of benefit
16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...
Posted by Michael Wonder on 16 Sep 2019
Canada decides: Leading parties plan to tackle ways to make medicine affordable
16 September 2019 - Canadian voters will be hearing a lot about a new national prescription drug program to fill a ...
Posted by Michael Wonder on 13 Sep 2019
Vertex announces new access agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)
12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ...
Posted by Michael Wonder on 13 Sep 2019
Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement
12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...
Posted by Michael Wonder on 13 Sep 2019
Taranaki man fearful drug funding change will bring back a life of seizures
13 September 2019 - For three years now a normal life has cost Nick Coulton $10 every three months. From ...
Posted by Michael Wonder on 12 Sep 2019
Batten disease treatment: parents win battle ahead of court date
11 September 2019 - Families of children with a rare degenerative disease have won their fight for funding for NHS ...
Posted by Michael Wonder on 12 Sep 2019
Public plans covered only 26% of the 491 new drugs approved by Health Canada from 2009 to 2018; national pharmacare is an empty promise for 23.2 million Canadians now covered by private plans
11 September 2019 - Two new studies confirm the abysmal state of access to innovative medicines in Canada’s publicly funded drug ...
Posted by Michael Wonder on 12 Sep 2019
New rules will keep the best medications from desperate Canadians
12 September 2019 - One reaction to recent amendments to the rules of the federal Patented Medicine Prices Review Board, ...
Posted by Michael Wonder on 12 Sep 2019
SMC U-turn for Vertex’s CF drugs
12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...
Posted by Michael Wonder on 12 Sep 2019
Kiwi cancer survival rates improving at slower rate than comparable countries, study shows
12 September 2019 - New Zealand is near the bottom for cancer survival compared to six other countries with similar ...
Posted by Michael Wonder on 11 Sep 2019
NICE publishes its 600th technology appraisal guidance
12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...
Posted by Michael Wonder on 11 Sep 2019
Children with rare inherited condition to benefit from drug through managed access agreement
11 September 2019 - It is estimated that in the UK there are around 30 to 50 children living with the ...
Posted by Michael Wonder on 11 Sep 2019
Germany may have the answer for reducing drug prices
11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...
Posted by Michael Wonder on 11 Sep 2019
Anti-depressant medicine brand switch: 'They've been used as guinea pigs'
11 September 2019 - Emotions ran high at the Health Select Committee today, with MPs grilling Medsafe and the Ministry ...
Posted by Michael Wonder on 11 Sep 2019
Government injects £130 million into cancer & debilitating illnesses
11 September 2019 - The UK government has announced an investment of over £130 million for new tech to tackle ...